Evidence map›Paper›PMID 36550419›Full record

ArticleBMC cancer2022

Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.

Nkafu Bechem Ndemazie, Andriana Inkoom, Dexter Ebesoh, Raviteja Bulusu, Esther Frimpong, Jose Trevino, Bo Han, Xue Zhu, Edward Agyare

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Nkafu Bechem NdemazieCollege of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, 1415 South Martin Luther King Jr Blvd, Tallahassee, FL, 32307, USA.
Andriana InkoomCollege of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, 1415 South Martin Luther King Jr Blvd, Tallahassee, FL, 32307, USA.
Dexter EbesohFaculty of Health Sciences, University of Buea, Buea, Cameroon.
Raviteja BulusuCollege of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, 1415 South Martin Luther King Jr Blvd, Tallahassee, FL, 32307, USA.
Esther FrimpongCollege of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, 1415 South Martin Luther King Jr Blvd, Tallahassee, FL, 32307, USA.
Jose TrevinoDepartment of Surgery, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Bo HanDepartment of Surgery, Keck School of Medicine University of South California, Los Angeles, CA, 90033, USA.
Xue ZhuCollege of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, 1415 South Martin Luther King Jr Blvd, Tallahassee, FL, 32307, USA. xue.zhu@famu.edu.
Edward AgyareCollege of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, 1415 South Martin Luther King Jr Blvd, Tallahassee, FL, 32307, USA. edward.agyare@famu.edu.
Florida Agricultural and Mechanical University · USUniversity of Buea · CMUniversity of Southern California · USVirginia Commonwealth University · US

Funding

Tissue Modeling & Drug Development Shared Resources CoreU54CA233444 · NCI · UNIVERSITY OF FLORIDA · PI Chanita A. Hughes-Halbert, Tianze Jiao · 2018 to 2026
$12.1M
Tissue Modeling CoreU54CA233465 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Bodour Salhia · 2018 to 2026
$11.9M
Tissue Modeling CoreU54CA233396 · NCI · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI Hernan Alcides Flores-Rozas · 2018 to 2026
$9.8M
NCI NIH HHS U54 CA233396NCI NIH HHS U54 CA233444NCI NIH HHS U54 CA233465
6 · The paper itself

Abstract

The failure of current chemotherapeutic agents for pancreatic cancer (PCa) makes it the most aggressive soft tissue tumor with a 5-year survival of slightly above 10% and is estimated to be the second leading cause of cancer death by 2030.

objectiveThe main aim was to synthesize, characterize and evaluate the anticancer activity of 1,3-bistetrahydrofuran-2yl-5FU (MFU).

methodsMFU was synthesized by using 5-fluorouracil (5-FU) and tetrahydrofuran acetate, and characterized by nuclear magnetic resonance (NMR), micro-elemental analysis, high-performance liquid chromatography (HPLC), and liquid chromatography with mass spectrophotometry (LC-MS). MFU and Gemcitabine hydrochloride (GemHCl) were tested for antiproliferative activity against MiaPaca-2 and Panc-1 cell lines.

resultsThe half-minimum inhibitory concentration (IC

conclusionMFU was synthesized with high purity and may have potential anticancer activity against PCa.

Indexed as

Antineoplastic AgentsPancreatic NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationFluorouracilGemcitabineMiceAntineoplastic AgentsFluorouracilGemcitabineApoptosisCytotoxicityImmunohistochemistryModified fluorouracilPancreatic cancer

Identifiers

PMID36550419
PMCPMC9773620
OpenAlexW4312075196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.